UAE biotech enterprise BioSapien collects $7 million in funds prior to Series A for their cancer treatment system
In a significant stride for cancer care, BioSapien, a biotech startup founded in 2018, has developed a groundbreaking technology: the MediChip, a 3D-printed micro-implant designed as a localised drug delivery platform for cancer treatment. This innovative device delivers chemotherapy drugs directly to tumours, aiming to reduce systemic side effects and improve treatment precision.
The MediChip consists of a biodegradable mesh that releases cancer drugs right at the tumour site, making chemotherapy less toxic and more accessible. This technology is not just a step forward in oncology but also in regions with limited access, such as the MENA region.
The MediChip represents a promising advancement in cancer care by combining 3D-printing technology with localised, biodegradable chemotherapy delivery. Initially, BioSapien will focus on colorectal cancer patients, but plans to expand to other cancers like pancreatic and lung cancer, as well as non-cancer applications.
BioSapien has recently secured an additional $7 million in funding, led by Golden Gate Ventures' MENA Fund. This investment reinforces the Gulf region's role as a global leader in healthcare innovation. Michael Lints, Partner at Golden Gate Ventures MENA, was impressed by Khatija Ali, CEO and Founder of BioSapien's passion and vision and sees the investment as supporting a groundbreaking technology.
Khatija Ali expressed her gratitude for the support, highlighting the investment's timing as they initiate clinical trials in Abu Dhabi. The startup plans to use the fresh funds for clinical trials in the UAE, set to begin in Q2 2025, product development, and scaling manufacturing capabilities.
The MediChip's simplified insertion protocols enable on-the-go therapy, supporting patient convenience and improved outcomes. This innovative platform addresses a critical need for more precise and less toxic cancer treatments, making it a promising solution for the future of cancer care.
The MediChip, a 3D-printed micro-implant, uses technology to combine 3D-printing with localised, biodegradable chemotherapy delivery for cancer treatment, aiming to reduce systemic side effects and improve precision. This innovative technology is not only a step forward in oncology but also in regions with limited access to advanced healthcare, such as the MENA region.
